Consano Bio Receives FDA Fast Track Designation for C-1101 in Chronic, Painful Lumbosacral Radiculopathy (LSR) or Chronic Sciatica

RegulatoryC-1101Positive

AI Analysis

Summary

Consano Bio received FDA Fast Track Designation for C-1101, a non-opioid biologic investigational drug for chronic painful lumbosacral radiculopathy and chronic sciatica, following clearance of the company's IND application.

Outcome Details

FDA Fast Track Designation granted; IND application cleared

Importance:7/10

Sentiment:

0.75

FDA Fast TrackIND clearancenon-opioidbiologicdisease-modifyingregulatory milestone

Read the original article

Published by PR Newswire Pharma on August 18, 2026 12:10 PM

Read Original